NHLBI TOPMed: Diabetes Heart Study (DHS) African American Coronary Artery Calcification (AA CAC)
Anthropometry (3)
- BMI - Body mass index (phv00310018.v1.p1)
- HEIGHT - Height (phv00310030.v1.p1)
- WEIGHT - Weight (phv00310029.v1.p1)
Biomarkers (10)
- ACR - Albumin creatinine ratio (phv00310028.v1.p1)
- CHOL - Cholesterol (phv00310038.v1.p1)
- CRP - C-reactive protein (phv00310042.v1.p1)
- DBP - Diastolic blood pressure (phv00310035.v1.p1)
- EGFR - Estimated glomelular filtration rate (phv00310027.v1.p1)
- HDL - High density lipoprotein cholesterol (phv00310039.v1.p1)
- LDL - Low density lipoprotein cholesterol (phv00310040.v1.p1)
- PULSE - Resting heart rate (phv00400174.v1.p1)
- SBP - Systolic blood pressure (phv00310034.v1.p1)
- TRIG - Triglycerides (phv00310041.v1.p1)
Demographics (3)
- AGE - Age (phv00310016.v1.p1)
- SEX - Sex (phv00310017.v1.p1)
- SEX - Sex (phv00310011.v2.p1)
Disease Events (4)
- AFFECTION_STATUS - Case control status of the subject for diabetes (phv00310006.v2.p1)
- DIABETES - Diabetes status at sample collection (phv00310020.v1.p1)
- GLUCOSE - Glucose (phv00310026.v1.p1)
- HBA1C - Hemoglobin A1c (phv00310025.v1.p1)
Imaging (4)
- AORTA_130 - Abdominal aortic calcified plaque using the agatston score with a 130 HU threshold (phv00310023.v1.p1)
- AVECAC_130 - Coronary artery calcified plaque using the agatston score with a 130 HU threshold (phv00310021.v1.p1)
- AVECAROTID_130 - Carotid artery calcified plaque using the agatston score with a 130 HU threshold (phv00310022.v1.p1)
- IMT - Intima-media thickness (phv00310037.v1.p1)
Medications (2)
- HYP_MED - Taking hypertension medication (phv00310036.v1.p1)
- LIPID_MED - Taking lipid medication (phv00400173.v1.p1)
Race and Ethnicity (1)
- RACE - Race (phv00310019.v1.p1)
Study Administration (1)
- CONSENT - Consent group as determined by DAC (phv00310005.v2.p1)
Other (26)
- ANALYTE_TYPE - Analyte Type (phv00310045.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00310044.v1.p1)
- DURATION - Years with diagnosed diabetes (phv00310024.v1.p1)
- FAMILY_ID - Family ID (phv00310007.v2.p1)
- FATHER - Father's Subject ID (phv00310009.v2.p1)
- Funding_Source - Project funding source (phv00400175.v1.p1)
- GENOTYPING_CENTER - Name of the center which conducted genotyping (phv00310048.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00310047.v1.p1)
- IS_TUMOR - Tumor status (phv00310046.v1.p1)
- MOTHER - Mother's Subject ID (phv00310010.v2.p1)
- NOTES - QC Notes (phv00400172.v2.p1)
- SAMPLE_ID - De-identified Sample ID (phv00310043.v1.p1)
- SAMPLE_ID - Sample ID (phv00310013.v1.p1)
- SAT - Subcutaneous adipose tissue (phv00310032.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00310049.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the SUBJECT_SOURCE repository (phv00400171.v2.p1)
- Study_Name - TOPMed-assigned short study name (1:1 with TOPMed phs number) (phv00400178.v1.p1)
- SUBJECT_ID - Unique sample id (phv00310015.v1.p1)
- SUBJECT_ID - Unique Subject ID (phv00310008.v2.p1)
- SUBJECT_ID - Subject ID (phv00310004.v2.p1)
- SUBJECT_ID - Subject ID (phv00310012.v1.p1)
- SUBJECT_SOURCE - Repository name for dbGaP study also containing this individual (phv00400170.v2.p1)
- TOPMed_Phase - TOPMed Phase (phv00400176.v1.p1)
- TOPMed_Project - TOPMed Project that funded sequencing (phv00400177.v1.p1)
- VAT - Visceral adipose tissue (phv00310031.v1.p1)
- VSR - Visceral-subcutaneous ratio (phv00310033.v1.p1)